Abiopharma

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, andTrodelvy® in MTAP-Deletion Urothelial Cancer

Real-World Evidence Supports Clinical Effectiveness ofneffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

New Form 8-K - HARROW, INC. Filed: 2025-09-08 AccNo: 0001493152-25-012778 Size: 324 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Vaxart Announces Adjournment of Special Meeting of Stockholders

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing

Mirum Pharma - Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

New Form 6-K - BELITE BIO, INC Filed: 2025-09-08 AccNo: 0001104659-25-088050 Size: 469 KB

New Form 6-K - ALTERITY THERAPEUTICS LTD Filed: 2025-09-08 AccNo: 0001213900-25-085289 Size: 33 KB

NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults

BullFrog AI’s bfPREP™ and bfLEAP®Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration